ConsumerAffairs2d
Mountjaro, Zepbound removed from FDA's shortage list
The FDA has removed two of Eli Lilly's in-demand weight-loss and diabetes drugs from its shortage list. Diabetes drug ...
Eli Lilly to build $4.5 billion research and manufacturing center to propel drug pipeline
Lilly has 11 obesity drugs in its pipeline and wants to develop more treatments for Alzheimer's disease, ALS and other brain ...
Eli Lilly to Invest $4.5B for New Manufacturing & Research Plant
The Medicine Foundry, which is expected to create 400 jobs, will be situated in the LEAP Research and Innovation District in ...
Drugmaker Lilly slates another $4.5B for manufacturing and drug development improvements
Eli Lilly is pouring another $4.5 billion into expanding drug manufacturing and development. The diabetes treatment maker ...
Lilly to invest $4.5 billion on new facility to scale-up pipeline drug production
U.S. drugmaker Eli Lilly said on Wednesday it will invest $4.5 billion to create a new center in Indiana that will focus on ...
Lilly looking to test Zepbound as health maintenance drug: report
Eli Lilly (LLY) is reportedly looking to study its weight-loss drug Zepbound in people who aren't considered overweight but ...
Eli Lilly and Company (LLY) Gets Strong Buy Rating Amid Revenue Growth
We recently published a list of 10 Best Healthcare Stocks To Buy According to Hedge Funds. In this article, we are going to ...
Eli Lilly announces $4.5 billion research and manufacturing facility in Lebanon LEAP district
Scheduled to open in late 2027, the site will combine research and manufacturing and increase the company's investment in the ...